Gain Therapeutics Inc (GANX) Hedge Fund Ownership (Q2 2026)

Q: Is it too late to buy Gain Therapeutics Inc (GANX) following the 2026 Q2 hedge fund 13F filings?

As of today, GANX has moved -6.6% since the 2026 Q2 13F filing date (August 14, 2026), compared to +4.3% for the XLV sector ETF — an outperformance of -10.9%. Since the quarter end (June 30, 2026), GANX gained -2.5% vs +10.1% for XLV. The stock is tracking its sector benchmark closely. The signal remains fresh and the entry point is still near the fund's implied reference.

Gain Therapeutics Inc (GANX)

49 + Investors. Track Smart Money conviction in GANX. See who's accumulating, reducing, or initiating positions.

Smart Money Signals — GANX

Based on 49 hedge funds · latest filing: 2026 Q2 · updated quarterly

📈

Buying streak — 1 quarter in a row

last 6Q

For 1 consecutive quarter, more hedge funds added GANX than sold it. That's a consistent pattern of professional buying — not a one-time trade. When institutions keep buying quarter after quarter, it usually means they see a multi-year opportunity, not just a short-term momentum flip.

🏔️

At the ownership peak (100% of max)

100% of all-time peak

49 hedge funds hold GANX right now — the highest count in 3.0 years. When ownership is this concentrated, any bad news can trigger a chain reaction: one big fund sells, others follow. This is a classic 'crowded trade' — high popularity doesn't equal safety.

🚀

Fast accumulation — +40% more funds vs a year ago

fund count last 6Q

+14 new funds entered over the past year (+40% YoY). That's a rapid rush of institutional money. Fast accumulation often signals a major thesis — but it also means the stock could fall quickly if that thesis breaks.

🟢

More buyers than sellers — 69% buying

29 buying13 selling

Last quarter: 29 funds were net buyers (13 opened a brand new position + 16 added to an existing one). Only 13 were sellers (9 trimmed + 4 sold completely). A clear majority buying is a strong confirmation signal.

📈

More new buyers each quarter (+6 vs last Q)

new funds entering per quarter

Funds opening a new GANX position: 9 → 21 → 7 → 13. A growing influx of new institutional buyers means the asset is still gathering momentum — the consensus hasn't fully saturated yet.

📌

Mixed — 33% long-term, 43% new

■ 33% conviction (2yr+) ■ 24% medium ■ 43% new

Of the 49 current holders: 16 (33%) held >2 years, 12 held 1–2 years, and 21 entered in the last year. A mixed base — the stock has long-term believers but also recent buyers who haven't been tested by a downturn yet.

📊

Peak discovery — momentum slowing

6 → 9 → 21 → 7 → 13 new funds/Q

New funds entering each quarter: 9 → 21 → 7 → 13. GANX is well-known in the hedge fund world, but fresh entries are gradually declining. The explosive phase of institutional discovery is likely behind us.

🏛️

Veteran-anchored — 43% veterans vs 42% newcomers

■ 43% veterans ■ 15% 1-2yr ■ 42% new

Entry-cohort mix of 53 holders: 23 (43%) are 2+ year veterans, 8 entered 1–2 years ago, and 22 (42%) joined within the past year. A veteran-weighted cap table skews toward institutional memory over fresh momentum.

✅

Strong quality — 29% AUM from major funds

29% from top-100 AUM funds

12 of 49 holders rank in the top 100 by AUM, accounting for 29% of total institutional value held. A meaningful share of the ownership value comes from the most well-resourced institutions.

4.3

out of 10

Moderate Exit Risk

Exit risk score 4.3/10 — some crowding factors present, but no critical concentration. Watch ownership trend over the next 1–2 quarters for direction.

Methodology note: these Smart Money cards use consecutive 13F disclosure snapshots, not trade-by-trade execution data. "Buying", "selling", "new holders", and "trimmed" refer to quarter-over-quarter changes in reported holders, aggregate shares, or disclosed position values between filings. They are useful for ownership regime analysis and crowding, but they do not imply exact trade timing on the filing date.

Metric	All 13F Filers (2026 Q2)	Prior (2026 Q1)	Change
Funds Holding	49	40	22.5%
13F Shares	9M	8M	5.92%
Total Value	$15M	$14M	6.28%
New Positions	13	7	+6
Increased Positions	14	10	+4
Closed Positions	4	16	-12
Reduced Positions	9	10	-1
Total Calls	3	3	-
Total Puts	1	1	-
PUT/CALL Ratio	0.33	0.33	Bullish

Metric

All 13F Filers (2026 Q2)

Prior (2026 Q1)

Change

Funds Holding

22.5%

13F Shares

5.92%

Total Value

$15M

$14M

6.28%

New Positions

Increased Positions

Closed Positions

-12

Reduced Positions

-1

Total Calls

Total Puts

PUT/CALL Ratio

0.33

Bullish

Institutional Holders (2026 Q2)

49 + investors

Explore institutional interest and hedge fund ownership dynamics. Analyze portfolio weights, new positions, and conviction trends in GANX. Verified SEC 13F-HR filings.

QUARTER:

FILTER:All New Added To Reduced No Change | Overweight >5%

Top 25 GANX holders by conviction (% of portfolio weight) — 2026 Q2 · Source: SEC Form 13F
#	Investor	% of Portfolio	Shares	Mkt Value
1	Potomac Capital Management, Inc.	1.31%	946,400	$1.9M
2	DME Capital Management, LP	0.03%	566,130	$1.1M
3	Benedict Financial Advisors Inc	0.01%	35,000	$71K
4	Millington Financial Advisors, LLC	0.01%	15,000	$26K
5	Oliver Luxxe Assets LLC	0.01%	20,250	$41K
6	Prelude Capital Management, LLC	0.01%	35,820	$73K
7	Stratos Wealth Partners, LTD.	0.00%	200,000	$406K
8	Marshall Wace, LLP	0.00%	1,923,546	$3.9M
9	Sandhill Capital Partners LLC	0.00%	15,400	$31K
10	Two Sigma Securities, LLC	0.00%	12,739	$26K
11	XTX Topco Ltd	0.00%	55,294	$112K
12	Cresset Asset Management, LLC	0.00%	160,000	$325K
13	Bridgeway Capital Management, LLC	0.00%	30,004	$61K
14	Apollon Wealth Management, LLC	0.00%	26,500	$54K
15	Jones Financial Companies Lllp	0.00%	608,592	$1.1M
16	Tower Research Capital LLC (TRC)	0.00%	8,321	$17K
17	Squarepoint Ops LLC	0.00%	136,359	$277K
18	Harbour Investments, INC.	0.00%	10,745	$22K
19	Wealthspire Advisors, LLC	0.00%	16,900	$34K
20	Commonwealth Equity Services, LLC	0.00%	58,456	$119K
21	HB Wealth Management, LLC	0.00%	12,783	$26K
22	Vanguard Fiduciary Trust Co	0.00%	231,534	$470K
23	Sanctuary Advisors, LLC	0.00%	10,000	$20K
24	NewEdge Advisors, LLC	0.00%	10,600	$22K
25	UBS Group AG	0.00%	215,012	$436K

Investor	Ownership History	% of Portfolio	Prev %	Rank	Conviction	Avg Buy Price	13F Score™ 3Y / 7Y	Sell Timing	Shares	Mkt Value	Change	Change %	Source	Quarter	Filed

Frequently Asked Questions — Gain Therapeutics Inc (GANX)

What does the Smart Money Trend signal show for GANX?

Buying streak — 1 quarter in a row: For 1 consecutive quarter, more hedge funds added GANX than sold it. That's a consistent pattern of professional buying — not a one-time trade. When institutions keep buying quarter after quarter, it usually means they see a multi-year opportunity, not just a short-term momentum flip.

What is the institutional breadth score for GANX?

More buyers than sellers — 69% buying: Last quarter: 29 funds were net buyers (13 opened a brand new position + 16 added to an existing one). Only 13 were sellers (9 trimmed + 4 sold completely). A clear majority buying is a strong confirmation signal.

What is the fund quality score for GANX holders?

Strong quality — 29% AUM from major funds: 12 of 49 holders rank in the top 100 by AUM, accounting for 29% of total institutional value held. A meaningful share of the ownership value comes from the most well-resourced institutions.

How long have hedge funds held GANX?

Mixed — 33% long-term, 43% new: Of the 49 current holders: 16 (33%) held >2 years, 12 held 1–2 years, and 21 entered in the last year. A mixed base — the stock has long-term believers but also recent buyers who haven't been tested by a downturn yet.

Is it too late to buy Gain Therapeutics Inc (GANX) following the 2026 Q2 hedge fund 13F filings?

As of today, GANX has moved -6.6% since the 2026 Q2 13F filing date (August 14, 2026), compared to +4.3% for the XLV sector ETF — an outperformance of -10.9%. Since the quarter end (June 30, 2026), GANX has gained -2.5% vs +10.1% for XLV. The stock is tracking its sector benchmark closely. The signal remains fresh and the entry point is still near the fund's implied reference.

Where does this institutional ownership data come from?

All holdings data is sourced from SEC Form 13F filings, which institutional investment managers with over $100 million in assets are required to submit quarterly. Data is parsed directly from SEC EDGAR.

Market Cap	--
Enterprise Value	--
Trailing P/E	--
Forward P/E	--
PEG Ratio (5yr expected)	--
Price/Sales (ttm)	--
Price/Book (mrq)	--
Enterprise Value/Revenue	--
Enterprise Value/EBITDA	--
Beta (5Y Monthly)	--
Short Ratio (Days to Cover)	--
Short % of Float	--

Profit Margin	--
Return on Assets (ttm)	--
Return on Equity (ttm)	--

Revenue (ttm)	--
Net Income Avi to Common (ttm)	--
Diluted EPS (ttm)	--
Total Cash (mrq)	--
Total Debt/Equity (mrq)	--
Levered Free Cash Flow (ttm)	--

Gain Therapeutics Inc (GANX)

Smart Money Signals — GANX

Buying streak — 1 quarter in a row

At the ownership peak (100% of max)

Fast accumulation — +40% more funds vs a year ago

More buyers than sellers — 69% buying

More new buyers each quarter (+6 vs last Q)

Mixed — 33% long-term, 43% new

Peak discovery — momentum slowing

Veteran-anchored — 43% veterans vs 42% newcomers

Strong quality — 29% AUM from major funds

Institutional Sentiment Summary — GANX

Hedge Fund Ownership: GANX

Market Analysis: GANX

Analyst Price Targets

Analyst Recommendations

Stock Performance

Company Profile: GANX

Is It Too Late to Buy Gain Therapeutics Inc (GANX) Based on Hedge Fund 13F Filings?

Hedge Fund Positioning: GANX

Statistics: GANX

Valuation Measures Data as of: --

Financial Highlights

Institutional Holders (2026 Q2)

Frequently Asked Questions — Gain Therapeutics Inc (GANX)

Welcome to 13Foresight!